Loading...

DMRA DAMORA THERAPEUTICS INC Company Mergers 8-K Filing

DMR

DMR

DAMORA THERAPEUTICS INC

(DMRA)

2024 8-K

Management Changes

Accounting Firm Change

Management Changes

Name Change Announcement

Stock Offering Announcement

Management Change

Investor Conference Update

Management Changes

Correction Filing

Merger Completion

Board Appointment

Asset Acquisition

Nasdaq Compliance

Annual Meeting Results

Deficiency Letter from Nasdaq

Positive trial results for ...

Clinical Trial Update

Restructuring Plan and Stra...

Phase 2b GALACTIC-1 Trial R...

Annual Meeting Results

FDIC Takeover of Silicon Va...

Financial Update

External Links:

Galecto, Inc. acquired global rights to Bridge Medicines' BRM-1420 program for treating acute myeloid leukemia, issuing 62,594 common shares and 160.562 preferred shares as part of the deal, which closed on October 7, 2024.

AI Assistant

DAMORA THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.